Skip to main content
. Author manuscript; available in PMC: 2016 Oct 18.
Published in final edited form as: Cancer. 2015 Dec 28;122(6):875–883. doi: 10.1002/cncr.29856

Figure 2.

Figure 2

Progression-free survival rates versus time for patients receiving Reolysin in combination with paclitaxel and carboplatin according to molecular abnormalities. The data are presented as months. EGFR indicates epidermal growth factor receptor.